Loading...

argenx SE

ARGNFPNK
Healthcare
Biotechnology
$718.05
$98.61(15.92%)

argenx SE (ARGNF) Financial Performance & Income Statement Overview

Access detailed quarterly and annual financial reports for argenx SE (ARGNF), covering cash flow, earnings, and balance sheets.

Revenue Growth
77.27%
77.27%
Operating Income Growth
94.91%
94.91%
Net Income Growth
372.54%
372.54%
Operating Cash Flow Growth
80.31%
80.31%
Operating Margin
13.47%
13.47%
Gross Margin
65.32%
65.32%
Net Profit Margin
48.33%
48.33%
ROE
19.13%
19.13%
ROIC
5.04%
5.04%

argenx SE (ARGNF) Income Statement & Financial Overview

Review argenx SE ARGNF income statement with detailed quarterly and annual figures.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue$1.30B$573.24M$841.96M$401.001M
Cost of Revenue$641.82M$59.07M$509.52M$43.18M
Gross Profit$661.43M$514.16M$332.44M$357.82M
Gross Profit Ratio$0.51$0.90$0.39$0.89
R&D Expenses$514.67M$235.94M$420.31M$224.97M
SG&A Expenses$563.64M$277.70M$254.28M$236.00M
Operating Expenses$548.27M$499.98M$462.09M$449.45M
Total Costs & Expenses$1.19B$559.05M$971.61M$492.63M
Interest Income$20.33M$40.59M$38.93M$38.90M
Interest Expense$704000.00$676000.00$572000.00$512000.00
Depreciation & Amortization$8.60M$74.51M$8.05M$24.05M
EBITDA$125.94M$88.70M-$118.50M-$54.53M
EBITDA Ratio$0.10$0.15-$0.14-$0.14
Operating Income$103.04M$14.19M-$129.65M-$93.42M
Operating Income Ratio$0.08$0.02-$0.15-$0.23
Other Income/Expenses (Net)-$16.53M$73.84M$46.24M$19.07M
Income Before Tax$86.51M$88.02M-$83.41M-$74.35M
Income Before Tax Ratio$0.07$0.15-$0.10-$0.19
Income Tax Expense-$687.65M-$3.39M-$52.57M-$12.75M
Net Income$835.54M$91.41M-$30.37M-$61.60M
Net Income Ratio$0.64$0.16-$0.04-$0.15
EPS$11.78$1.52-$0.51-$1.04
Diluted EPS$11.78$1.39-$0.51-$1.04
Weighted Avg Shares Outstanding$70.95M$60.09M$59.40M$59.31M
Weighted Avg Shares Outstanding (Diluted)$70.96M$65.76M$59.40M$59.31M

The company's financials show resilient growth, with revenue advancing from $401.001M in Q1 2024 to $1.30B in Q4 2024. Gross profit remained healthy with margins at 51% in Q4 2024 compared to 89% in Q1 2024. Operating income hit $103.04M last quarter, sustaining a consistent 8% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $125.94M. Net income rose to $835.54M, while earnings per share reached $11.78. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;